8-K: BioNexus Gene Lab Corp. Granted Extension to Regain Nasdaq Compliance, Plans Reverse Stock Split

BioNexus Gene Lab Corp. has received an extension until May 1, 2025, to meet Nasdaq's minimum bid price requirement and plans a reverse stock split by April 7, 2025, if necessary.

Summary

• BioNexus Gene Lab Corp. received a notice from the Nasdaq Hearings Panel on December 27, 2024, granting an extension to regain compliance with the minimum bid price rule of $1.00 per share.
• The company has until May 1, 2025, to meet this requirement.
• To achieve compliance, BioNexus Gene Lab Corp. intends to implement a reverse stock split, if necessary, by April 7, 2025.
• Failure to meet the compliance deadline will result in the delisting of the company's common stock from the Nasdaq Capital Market.
• Nasdaq has updated its rules regarding reverse stock splits, requiring the company to notify Nasdaq at least ten calendar days before the market effective date of the split, effective January 30, 2025.

Sentiment

Score: 4

Explanation: The document indicates a negative situation with the company's stock price and potential delisting, but also shows a plan to address the issue. The sentiment is therefore negative but not extremely so.

Positives

• The company has been granted an extension to regain compliance with Nasdaq listing rules, avoiding immediate delisting.
• BioNexus Gene Lab Corp. has a clear plan to regain compliance, including a potential reverse stock split.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price rule.
• There is a risk of delisting if the company fails to regain compliance by May 1, 2025.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market if it does not regain compliance by May 1, 2025.
• The reverse stock split may not be sufficient to raise the share price above $1.00 per share.
• The company must adhere to new Nasdaq rules regarding reverse stock split notifications, effective January 30, 2025.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing rules and will provide updates as appropriate.

Management Comments

• The company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance, particularly during periods of market volatility. Reverse stock splits are a common strategy to address low share prices.

Comparison to Industry Standards

• Other companies facing similar delisting notices from Nasdaq include those in the biotechnology and small-cap sectors, such as XOMA Corporation which received a delisting notice in 2023 before regaining compliance.
• Reverse stock splits are a common tool used by companies to regain compliance, with examples including companies like Ocugen, Inc. which implemented a reverse stock split in 2023 to meet Nasdaq's minimum bid price requirement.
• The timeline provided to BioNexus Gene Lab Corp. is consistent with the typical timeframe granted by Nasdaq for companies to regain compliance.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company fails to regain compliance.
• The reverse stock split could impact the value of existing shares.

Next Steps

• The company will implement a reverse stock split, if necessary, by April 7, 2025.
• The company will notify Nasdaq at least ten calendar days before the market effective date of the reverse stock split, starting January 30, 2025.
• The company will provide updates as appropriate regarding its compliance efforts.

Key Dates

Keywords

Nasdaq, delisting, compliance, reverse stock split, minimum bid price, BGLC